Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Norgine Pharmaceuticals Limited, Norgine House, Widewater Place, Moorhall Road, Harefield, Uxbridge, UB9 6NS, UK
Angusta 25 microgram tablets.
| Pharmaceutical Form |
|---|
|
Tablet. White, uncoated oval shaped tablets with the dimensions 7.5 × 4.5 mm with a score line on one side and plain on the other.The score line is not intended for breaking the tablet. |
Each tablet contains 25 micrograms misoprostol.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Misoprostol |
Misoprostol is an analogue of naturally occurring prostaglandin E1 which promotes peptic ulcer healing and symptomatic relief. Misoprostol protects the gastroduodenal mucosa by inhibiting basal, stimulated and nocturnal acid secretion and by reducing the volume of gastric secretions, the proteolytic activity of the gastric fluid, and increasing bicarbonate and mucus secretion. |
| List of Excipients |
|---|
|
Hypromellose |
Angusta is available in a pack of double layer aluminium foil blister containing 8 tablets.
Norgine Pharmaceuticals Limited, Norgine House, Widewater Place, Moorhall Road, Harefield, Uxbridge, UB9 6NS, UK
PL 20011/0072
Date of first authorisation: 02 September 2020
| Drug | Countries | |
|---|---|---|
| ANGUSTA | Austria, Estonia, Finland, France, Croatia, Ireland, Malta, Netherlands, Poland, Romania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
